
News|Articles|February 1, 2010
FDA Pipeline preview, February 2010 (Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone, Davunetide, BiovaxID, EpiCept, CP-4126)
Recent FDA action (through February 2010) related to Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone, Davunetide, BiovaxID, EpiCept, CP-4126
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio
2
Patients may not see savings from new Medicare drug programs
3
FDA accepts NDA for gedatolisib, Celcuity’s investigational breast cancer treatment
4
Why Timing, Access and Interpretation Matter in Oncology Biomarker Testing
5




















































